Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Lama

Showing results (191-200 of 226) with videos related to

Pageof 23
Sort By:
Science (New York, N.Y.)|October 1, 2005
AIDS. Promote HIV chemoprophylaxis research, don't prevent itRobert M Grant, Susan Buchbinder, Willard Cates, et al.
Science Translational Medicine|September 14, 2012
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with menPeter L Anderson, David V Glidden, Albert Liu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 18, 2014
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx StudyAlbert Liu, David V Glidden, Peter L Anderson, et al.
Plos One|August 26, 2014
Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trialSteven A Safren, Katie B Biello, Laura Smeaton, et al.
Clinical Nutrition (Edinburgh, Scotland)|February 24, 2015
Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adultsRupak Shivakoti, Parul Christian, Wei-Teng Yang, et al.
The Journal of Infectious Diseases|December 2, 2015
Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained SettingsRupak Shivakoti, Wei-Teng Yang, Sima Berendes, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 19, 2007
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120Farley Cleghorn, Jean W Pape, Mauro Schechter, et al.
Open Forum Infectious Diseases|July 28, 2022
Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden SettingsAmita Gupta, Xin Sun, Sonya Krishnan, et al.
Frontiers in Immunology|November 27, 2020
Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical StudyJorge Sanchez, Elena Gonçalves, Anuska Llano, et al.
AIDS and Behavior|November 10, 2017
Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with MenAlex Carballo-Diéguez, Rebecca Giguere, Curtis Dolezal, et al.
Pageof 23

Showing results (191-200 of 226) with videos related to

Sort By:
Pageof 23
Science (New York, N.Y.)|October 1, 2005
AIDS. Promote HIV chemoprophylaxis research, don't prevent itRobert M Grant, Susan Buchbinder, Willard Cates, et al.
Science Translational Medicine|September 14, 2012
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with menPeter L Anderson, David V Glidden, Albert Liu, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 18, 2014
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx StudyAlbert Liu, David V Glidden, Peter L Anderson, et al.
Plos One|August 26, 2014
Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trialSteven A Safren, Katie B Biello, Laura Smeaton, et al.
Clinical Nutrition (Edinburgh, Scotland)|February 24, 2015
Prevalence and risk factors of micronutrient deficiencies pre- and post-antiretroviral therapy (ART) among a diverse multicountry cohort of HIV-infected adultsRupak Shivakoti, Parul Christian, Wei-Teng Yang, et al.
The Journal of Infectious Diseases|December 2, 2015
Persistently Elevated C-Reactive Protein Level in the First Year of Antiretroviral Therapy, Despite Virologic Suppression, Is Associated With HIV Disease Progression in Resource-Constrained SettingsRupak Shivakoti, Wei-Teng Yang, Sima Berendes, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 19, 2007
Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120Farley Cleghorn, Jean W Pape, Mauro Schechter, et al.
Open Forum Infectious Diseases|July 28, 2022
Isoniazid Adherence Reduces Mortality and Incident Tuberculosis at 96 Weeks Among Adults Initiating Antiretroviral Therapy With Advanced Human Immunodeficiency Virus in Multiple High-Burden SettingsAmita Gupta, Xin Sun, Sonya Krishnan, et al.
Frontiers in Immunology|November 27, 2020
Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical StudyJorge Sanchez, Elena Gonçalves, Anuska Llano, et al.
AIDS and Behavior|November 10, 2017
Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with MenAlex Carballo-Diéguez, Rebecca Giguere, Curtis Dolezal, et al.
Pageof 23